Bejelentkezés Regisztrálj ingyen

Æterna Zentaris FCF yield

Mi az Æterna Zentaris FCF yield?

A FCF yield az Æterna Zentaris, Inc. - -96.08%

Mi a FCF yield meghatározása?



Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.

ttm (trailing twelve months)

Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.

Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:

Free cash flow yield = Free cash flow per share / market price per share

FCF yield a Health Care szektor a TSX-on cégekben a Æterna Zentaris -hoz képest

Mit csinál Æterna Zentaris?

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

fcf yield -hoz hasonló cégek Æterna Zentaris